Recombinant Danio rerio ACER1 is produced in heterologous expression systems such as E. coli and mammalian cells (e.g., HEK293) . Key features include:
The protein is typically stored in lyophilized or liquid form at -20°C/-80°C, with a shelf life of 6–12 months . Reconstitution involves dissolving in deionized water and adding glycerol (5–50%) for stability .
ACER1 regulates sphingolipid balance by converting ceramides into sphingosine, which is further phosphorylated to sphingosine-1-phosphate (S1P) . This activity is critical for:
Epidermal differentiation: ACER1-deficient mice exhibit transepidermal water loss and cyclic alopecia due to ceramide accumulation .
Antimicrobial defense: Releases sphingoid bases in the stratum corneum to combat pathogens .
Cellular stress responses: Modulates apoptosis and proliferation in keratinocytes .
Acer1-knockout mice showed elevated ceramide levels, disrupted hair shaft cuticles, and impaired skin barrier function, underscoring its role in epidermal integrity . ACER1 expression is upregulated during calcium-induced keratinocyte differentiation, linking it to terminal differentiation pathways .
A 2024 study identified ACER1 as a downstream target of the manganese transporter SLC39A8. Inhibition of ACER1 with D--erythro-MAPP restored sphingomyelin levels and mitigated colitis in Slc39a8-deficient mice, highlighting its role in intestinal epithelial integrity .
Disease modeling: Used to study skin disorders and leukodystrophy linked to ceramide dysregulation .
Drug development: ACER1 inhibitors like D--erythro-MAPP are explored for inflammatory bowel disease and cancer .
Enzyme kinetics: Characterized for substrate specificity toward very-long-chain ceramides .
While recombinant ACER1 enables mechanistic studies, its membrane-associated nature complicates purification . Future work may focus on: